Company: CPSH
Filing Date: 2025-10-06
Form Type: 424B5
Source: 0001437749-25-030558
Chunk: 9

Company: CPS TECHNOLOGIES CORP/DE/
Filing Date: 2025-10-06
Form: 424B5
Chunk 9
---
      |
| Net tangible book value per share as of June 28, 2025                               |     | $ | 1.02 |
| Increase in net tangible book value per share attributable to existing stockholders |     | $ |      |
| As adjusted net tangible book value per share after giving effect to this offering  |     | $ |      |
| Dilution per share to investors participating in this offering                      |     | $ |      |

If the underwriters exercise in full their option to purchase additional shares from us, the as adjusted net tangible book value per share after this offering would be $ per share, the increase in net tangible book value per share to existing stockholders would be $ per share and the dilution to new investors purchasing shares in this offering would be $ per share.

The number of shares of common stock to be outstanding immediately after this offering is based on 14,529,277 shares outstanding as of June 28, 2025, which excludes:

| • | 1,077,800 shares of common stock issuable upon the exercise of outstanding stock options as of June 28, 2025, with a weighted-average exercise price of $2.45 per share; |

| • | 421,400 shares of common stock reserved for future issuance under our 2020 Plan; |

To the extent any options are exercised or restricted stock units vest, new options, restricted stock awards or restricted stock units are issued under our equity incentive plans, or we otherwise issue additional shares of common stock in the future, there will be further dilution to new investors.

In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or debt securities, the issuance of these securities could result in further dilution to our stockholders.

<div align='center'>S-7

UNDERWRITING</div>

We have entered into an underwriting agreement dated October , 2025 with Roth Capital Partners, LLC, as the representative of the underwriters in this offering. Subject to the terms and conditions of the underwriting agreement, the underwriters have agreed to purchase the number of our shares of common stock set forth opposite its name below.

| Underwriter                | Number of Shares |
| Roth Capital Partners, LLC |                  |
| Total                      |                  |

A copy of the underwriting agreement will be filed as an exhibit to a